ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

æÇÃÀGLP-1¶àëĹú¼ÊÃ÷ÐDzúÆ·£¡ÄϹ¬¶àëÄÐÂÒ©ÔÚ·ÊÅÖÒ½ÖÎÁìÓò»ñµÃÁÙ´²Ç°ÐÂÍ»ÆÆ

ÈÕÆÚ£º

2026Äê04ÔÂ02ÈÕ 14:40


ÔÚ·ÊÅÖ¼°ÓйشúлÐÔ¼²²¡³ÉΪȫÇòÐÔ½¡È«Ìôսȷµ±Ï £¬ÄϹ¬£¨ÒÔϼò³Æ“ÄϹ¬”£©´«À´Õñ·ÜÈËÐĵÄÐÂÎÅ£¡Æä×ÔÖ÷Ñз¢µÄ´´ÐÂÓ×·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£© £¬ÔÚÕë¶ÔDB/DB·ÊÅÖÓ×ÊóÄ£Ð͵ÄÁÙ´²Ç°×êÑÐÖÐ £¬Õ¹Ê¾³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõ³Á³ÉЧ £»½áºÏÆä¶Ô¼¡ÈâµÄά³Ö×÷Óà £¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷½Ú×÷Óà £¬ÓÐÍû´øÀ´²î¾à»¯µÄÁÙ´²Ñ¡Ôñ ¡£

Ò»¡¢¾ªÑ޵ļõ³ÁÊý¾Ý

DB/DBÓ×ÊóÊÇ×êÑзÊÅÖºÍ2ÐÍÌÇÄò²¡µÄ¾­µä¶¯ÎïÄ£ÐÍ £¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌåÖ°ÄÜȱµã £¬²û·¢³öÑϳÁµÄ·ÊÅÖ¡¢¸ßѪÌǺʹúл´íÂÒµÈÖ¢×´ ¡£ÔÚÄϹ¬·¢Õ¹µÄÕâÏîÁÙ´²Ç°×êÑÐÖÐ £¬¹«Ë¾×ÔÑеÄÓ×·Ö×Ó»·ëÄչʾ³öÓÅÒìµÄ¼õ³Á³ÉЧ ¡£

ÊÔÑéÁ˾ÖÏÔʾ £¬¾­¹ýΪÆÚ8ÖܵÄÒ½ÖÎ £¬Óë¿Õȱ¶ÔÕÕ×éDB/DBÓ×ÊóÏà±È £¬MCR»·ëĽϸ߼ÁÁ¿×éµÄÓ×ÊóµÄÌå³Á½µÂä·ù¶ÈԼΪGLP-1¶àëÄ×éµÄ1.25±¶ £¬Ê¹DB/DBÓ×ÊóµÄÌå³ÁÔö³¤Ç÷ÏòÏÔÖø·Å»º £¬¿¿½ü½¡È«¶ÔÕÕ×éˮƽ ¡£

 

c8b77f12-0cf6-4a72-b0dc-d6a3a99dfdb2

 

¶þ¡¢¶àÏî´úлָ±êÈ«Ãæ¸ÄÉÆ

MCR»·ëĽϸ߼ÁÁ¿×éÔÚ¸ÄÉÆ¸ÊÓÍÈýõ¥£¨TG£©¡¢¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼£¨HDL-C£©¡¢ÑªÌÇ¡¢ÄòÌÇˮƽ·½Ãæ £¬Í¬Ñù²û·¢ÓÅÒ죺

1.TGˮƽ£ºÏÔÖø½µµÍDB/DBÓ×ÊóµÄTGˮƽ £¬ÓÅÓÚGLP-1¶àëÄ×é £»

2.HDL-Cˮƽ£ºÏÔÖøÉý¸ß £¬ÓÅÓÚGLP-1¶àëÄ×é £»ÓÐÖúÓÚ½µµÍ¶¯ÂöÖàÑùÓ²»¯·çÏÕ £»

3.ѪÌÇˮƽ£ºÒ½ÖÎ6ÖܵĽµµÍѪÌÇŨ¶ÈˮƽÓëGLP-1¶àëÄ×é¿¿½ü £»

4.ÄòÌÇˮƽ£ºÒ½ÖÎ8Öܽ«ÄòÌÇˮƽ´Ó»ùÏß½µÖÁÒ»°ë £»

5.ÌÇ»¯Ñªºìµ°°×£¨HbA1c£©£ºÓëÄ£ÐÍ×éÏà±È £¬HbA1c½µÂä·ù¶È´ïÔ¼1/3 ¡£

|½áºÏDZÁ¦

ÖµµÃÒ»ÌáµÄÊÇ £¬ÄϹ¬ÒÑ·¢Õ¹ÁË»·ëÄÓëGLP-1ÀàÒ©ÎÈçGLP-1¶àëÄ£©½áºÏʹÓõÄ×êÑÐ £¬Á˾ÖÏÔʾÔÚÒûʳÓÕµ¼µÄ·ÊÅÖÓ×ÊóÄ£ÐÍÖÐ £¬Á½ÕßÔÚ¼õ³Á³ÉЧ¼°¼¡Èâ± £»¤·½ÃæÓµÓÐÃ÷È·µÄЭͬЧӦ£º

1.Эͬ¼õ³Á£º½áºÏÓÃÒ©×é²û·¢³ö¸üÏÔÖøµÄ¼õ³Á³ÉЧ £¬ÓÅÓÚµ¥Ò©Ò½ÖÎ £»

2.Ï÷¼õ¼¡ÈâÁ÷ʧ£º»·ëÄÔÚÁªÓÃÖÐÓÐЧ»º½âGLP-1ÀàÒ©Îï´øÀ´µÄ¼¡ÈâÁ÷ʧÎÊÌâ £¬Ìá¸ßÕûÌåÒ½Öΰ²È«ÐÔ ¡£

Èý¡¢¶à°ÐµãЭͬ×÷Ó㺻·ëĵĴ´Ð»úÔì

MCR»·ëÄÖ®ËùÒÔ¿ÉÄÜÔÚ¼õ³Á¼°ÆäËû´úлָ±êÉÏ»ñµÃÈç´ËÓÅÒìµÄ³É¾Í £¬ÓëÆä¹ÖÒìµÄ×÷ÓûúÔìÃܲ»³É·Ö ¡£×÷ΪһÖÖÓ×·Ö×Ó»·ëÄÒ©Îï £¬¿ÉÄÜͬʱ¾«×¼×÷ÓÃÓÚMC4RºÍMC1RÁ½¸ö¹Ø¼ü°Ðµã £¬Í¨¹ý¶à°ÐµãЭͬ×÷Óà £¬²ûÑïÆä׿ԽµÄ´úлµ÷½Ú¹¦Ð§ ¡£

|¼¤»îMC4R£ºÒÖÔìʳÓû £¬ÍƽøÖ¬·¾·Ö»¯

MC4RÊÇÖÐÊàÉñ¾­ÏµÍ³µ÷¿ØÄÜÁ¿Æ½ºâµÄ¹Ø¼üÊÜÌå ¡£ÄϹ¬MCR»·ëÄ×÷ΪMC4R¼¤°º¼Á £¬¿ÉÄÜÍÆ½øÖ¬·¾·Ö»¯ £¬ÒÖÔìÖ¬·¾ÌìÉú £»Íƽø°×ɫ֬·¾×éÖ¯ºÖ±ä £»Ìá¸ßÒȵºËØÃô¸ÐÐÔ £»ÔÚ²»ÏÔÖøÒÖÔìʳÓûµÄǰÌáÏÂʵÏÖ¼õÖ¬ £¬Ô¤·ÀÑáʳ¸±×÷ÓÃ1 ¡£

 

528820a7-b432-4eb8-9319-127f44137ade

 

|¼¤»îMC1R:¿¹Ñ×ÃâÒßµ÷½Ú £¬¸´Ô­ÊÝËØÃô¸ÐÐÔ

MC1RÖØÒª²Î¼ÓÃâÒßµ÷½ÚºÍÑ×Ö¢·´Ó³ ¡£Í¨¹ý¼¤»îMC1R £¬¿ÉÄÜÏÔÖø¸ÄÉÆÌåÄÚÑ×֢΢»·¾³ £¬½µµÍÑ×Ö¢Òò×Ó£¨Ô̺¬IL-1, TNF-a, IL-6, IL-8, and IL-12, iNOSµÈ£©µÄ±í°×´Ó¶ø¸´Ô­ÊÝËØÃô¸ÐÐԺ͵÷½ÚÃâÒß·´Ó³ £¬¶Ô×ÔÉíÃâÒßÐÔ¼²²¡ÓµÓÐDZÔÚÒ½ÖμÛÖµ2 ¡£

2e9e4ae7-cbd8-4c9e-81e8-a16269e2f9a9

ËÄ¡¢ÁÉÀ«µÄÀûÓÃÔ¶¾°£º´úл´íÂÒÓë×ÔÉíÃâÒßÊÊÓ¦Ö¢

»ùÓÚMCR»·ëÄÔÚÁÙ´²Ç°×êÑÐÖÐչʾ³öµÄ׿Խ¼õ³Á³ÉЧºÍ¶àϵͳ´úл¸ÄÉÆ×÷Óà £¬ÄϹ¬¶ÔÆä½«À´ÔÚ´úлºÍ×ÔÃâÁìÓòÖеÄÀûÓÃÔ¶¾°³ä³âÐÅÄî ¡£

´úл×ÛºÏÕ÷¼°Æä²¢·¢Ö¢·½Ãæ £¬MCR»·ëIJ»½öÄܼõ³Á £¬»¹ÄÜͬ²½¸ÄÉÆÑªÌÇ¡¢ÑªÖ¬¡¢HbA1c¡¢ÄòÌǵȶàÏîÖ¸±ê £¬¶Ô2ÐÍÌÇÄò²¡¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡¡¢¸ßѪѹ¡¢¶¯ÂöÖàÑùÓ²»¯µÈ´úл×ÛºÏÕ÷×é·ÖÖ®Ò»»ò¶àÏîÓµÓйýÎÊDZÁ¦ ¡£

×ÔÉíÃâÒßÓëÑ×Ö¢Óйؼ²²¡·½Ãæ £¬ÓÉÓÚÆä¾ß±¸ÏÔÖøµÄ¿¹Ñ׺ÍÃâÒßµ÷½Ú×÷Óà £¬½«À´ÓÐÍûÍØÕ¹ÖÁÀà·çʪÐԹؽÚÑ× £»ÂýÐÔÉö² ¡£¨CKD£© £»ÌÇÄò²¡Éö² ¡£¨DN£©µÈÊÊÓ¦Ö¢ ¡£

½ÓÏÂÀ´ £¬¹«Ë¾½«³ÖÐøÍÆ¶¯¶àëÄÐÂÒ©µÄÁÙ´²Ç°Ò©ÀíѧºÍ¶¾Àíѧ×êÑÐ £¬ÕùÈ¡ÔçÈÕ½«ÐÂÒ©ÍÆÏòÁÙ´²½×¶Î £¬ÔÚÒÑÊÚȨµÄרÀû¼Ó³ÖÏ £¬¼±¾ç½«²î¾à»¯µÄºÃÒ©´ø¸øÕ¼ÓÐÓйØÒ½ÖÎÐèÒªµÄ»¼ÕßȺÌå ¡£

ÎÄÕÂÆðÔ´ÓÚҩʱÆÚ¹«¼ÒºÅ

²Î¿¼Îļþ

1. Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022). Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal transduction and targeted therapy, 7(1), 298.https://doi.org/10.1038/s41392-022-01149-x

2. Mun, Y., Kim, W., & Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. International journal of molecular sciences, 24(15),12152. https://doi.org/10.3390/ijms241512152

ÓйØÍƼö

¡¾ÍøÕ¾µØÍ¼¡¿